Status:
COMPLETED
NGS Genome Analysis in Personalisation of Lung Cancer Treatment
Lead Sponsor:
Centre Georges Francois Leclerc
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The identification of driver mutations in the epidermal growth factor receptor (EGFR) as the primary oncogenic event in a subset of lung adenocarcinomas led to a model of targeted treatment and geneti...
Eligibility Criteria
Inclusion
- patients of bronchial adénocarcinoma with metastases can benefit from first-line therapy - targeted therapy by tyrosine kinase inhibitor(TKI) for EGFR mutation and chemotherapy for non EGFR mutation)
- Patients with epidermoid cancer of the lungs can benefit from chemotherapy
- man and women
- age ≥ 18 years
- Patients have signed a written informed consent form
- Patients are affiliated to s social health insurance
Exclusion
- Survival time ≤ 3 months
- Patients with cerebral metastases
- Patients could not benefit from treatment for others diseases
- Pregnancy or breast-feeding
- Incapacity to sign the consent form for psychiatric, behavioural disorders
- Private individuals of freedom or under tutelage
Key Trial Info
Start Date :
October 24 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 17 2018
Estimated Enrollment :
165 Patients enrolled
Trial Details
Trial ID
NCT02281214
Start Date
October 24 2014
End Date
November 17 2018
Last Update
January 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Georges François Leclerc
Dijon, France, 21000